Bio-Techne (TECH) Q2 2026 earnings review
Profitability Improved, But Organic Growth Stalls
Bio-Techne delivered a mixed Q2. While Adjusted EPS of $0.46 beat the prior year ($0.42) and Adjusted Operating Margins expanded 100bps to 31.1%, the top line remains stagnant. Organic revenue was flat (0%), marking a slight improvement from the -1% contraction in Q1 but confirming that a broad-based recovery remains elusive. The margin beat was driven by the Diagnostics segment (aided by the Exosome Diagnostics divestiture) and cost cuts, masking a concerning deterioration in the core Protein Sciences segment, where margins compressed nearly 200bps and organic revenue fell 1%.
🐂 Bull Case
The company delivered double-digit growth in its largest end market, large pharma, for the fourth consecutive quarter. This segment remains a resilient engine despite broader macro weakness.
The Diagnostics and Spatial Biology segment is transforming. Following the divestiture of the drag-heavy Exosome Diagnostics business, operating margins in this segment leaped to 10.4% from 3.9% a year ago.
🐻 Bear Case
Protein Sciences, the company's crown jewel, is showing cracks. Organic revenue declined 1% and operating margins compressed significantly (39.3% vs 41.2% prior year) due to unfavorable product mix. Reliance on cost cuts to drive EPS is not sustainable without core volume growth.
Organic growth has decelerated from 9% a year ago to flat (0%) today. While 'stabilizing,' the lack of growth indicates persistent weakness in Academic and Biotech funding environments.
⚖️ Verdict: ⚪
Neutral. The margin discipline and portfolio pruning (Exosome divestiture) are commendable and protected earnings. However, the degradation in the core Protein Sciences segment—both in sales and margin—is a major concern that prevents a bullish stance until volume growth returns.
Key Themes
Protein Sciences Margin Compression
A red flag emerged in the core Protein Sciences segment. Despite being the primary profit engine, operating margins fell to 39.3% from 41.2% a year ago. Management cited 'unfavorable product mix' as the primary culprit, partially offsetting productivity initiatives. This suggests that while low-margin Diagnostics improved, the high-margin core business is facing pricing or mix pressure.
Diagnostics Segment Turnaround
The Diagnostics and Spatial Biology segment posted a remarkable profitability turnaround. Operating margins expanded to 10.4% from just 3.9% in the prior year. This was driven by the divestiture of the loss-making Exosome Diagnostics business and volume leverage (3% organic growth). This structural fix removes a long-standing drag on corporate margins.
Large Pharma Resilience
Large pharma continues to be the singular bright spot in the demand picture. For the fourth consecutive quarter, this end market delivered double-digit growth. This consistency suggests Bio-Techne's tools remain critical for drug development workflows even as customers scrutinize budgets.
China Recovery
China/APAC grew for the third consecutive quarter. This differentiates Bio-Techne from many peers who are still reporting contractions in the region. Management cited 'improving end-markets' and strong commercial execution, though the specific magnitude was not quantified in the release.
Unfavorable Product Mix
Unfavorable product mix was cited explicitly as a headwind for both GAAP and Adjusted operating margins in the release. This implies that growth is skewing towards lower-margin instruments or services rather than the high-margin consumables that typically drive Bio-Techne's profitability profile.
Other KPIs
Beat/Accelerating. Up 9.5% YoY from $0.42. The growth in earnings despite flat revenue highlights significant operational leverage and cost control measures.
Decelerating. Organic revenue declined 1%. This segment has struggled to return to growth in FY26 (Q1 was -3% organic), indicating persistent headwinds in the academic and biotech customer bases.
Accelerating. Up 100bps YoY from 30.1% and up 120bps sequentially from 29.9% in Q1. The removal of Exosome Diagnostics is proving accretive.
Guidance
The earnings release did not provide specific numeric guidance tables. Management stated results were 'largely in line with our expectations.' Note: In the prior quarter (Q1), management guided for a return to growth in the second half of the fiscal year.
Key Questions
Protein Sciences Margin Deterioration
Operating margin in Protein Sciences dropped nearly 200bps YoY to 39.3%. With Large Pharma growing double-digits, why is mix so unfavorable? Is this pricing pressure or a shift to lower-margin instruments?
China Sustainability
China has grown for three consecutive quarters. Is this driven by stimulus and underlying demand, or are we seeing stocking ahead of potential trade policy changes?
Academic/Biotech Recovery Timeline
With organic growth flat and Large Pharma growing double-digits, the implied drag from Academia and Biotech remains severe. When do you model these segments crossing back into positive territory?